GERON CORP Investment Income, Interest
GERON CORP (GERN) reported Investment Income, Interest of $2.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- GERON CORP investment income, interest for the quarter ending 2026-06-30 was $2.97M, a 36.19% decline year-over-year.
- GERON CORP investment income, interest for the quarter ending 2026-03-31 was $3.42M, a 33.60% decline year-over-year.
- GERON CORP investment income, interest for the quarter ending 2025-12-31 was $4.04M, a 21.59% decline year-over-year.
- GERON CORP investment income, interest for the quarter ending 2025-09-30 was $4.26M, a 12.57% decline year-over-year.
- GERON CORP investment income, interest for fiscal 2025 was $18.12M, a 7.60% decline from fiscal 2024.
- GERON CORP investment income, interest for fiscal 2024 was $19.61M, a 8.02% increase from fiscal 2023.
- GERON CORP investment income, interest for fiscal 2023 was $18.15M, a 617.75% increase from fiscal 2022.
- GERON CORP investment income, interest for fiscal 2022 was $2.53M, a 379.89% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.97M 10-Q · filed 2026-08-05 | $6.39M 10-Q · filed 2026-08-05 | $10.44M derived: sum of 3 quarters · filed 2026-08-05 | $14.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.42M 10-Q · filed 2026-05-06 | $7.47M derived: sum of 2 quarters · filed 2026-05-06 | $11.73M derived: sum of 3 quarters · filed 2026-05-06 | $16.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.31M derived: sum of 2 quarters · filed 2026-03-02 | $12.96M derived: sum of 3 quarters · filed 2026-08-05 | $18.12M 10-K · filed 2026-03-02 |
| 2025-09-30 | $4.26M 10-Q · filed 2025-11-07 | $8.92M derived: sum of 2 quarters · filed 2026-08-05 | $14.07M 10-Q · filed 2025-11-07 | $19.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.66M 10-Q · filed 2026-08-05 | $9.81M 10-Q · filed 2026-08-05 | $14.97M derived: sum of 3 quarters · filed 2026-08-05 | $19.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $5.15M 10-Q · filed 2026-05-06 | $10.31M derived: sum of 2 quarters · filed 2026-05-06 | $15.19M derived: sum of 3 quarters · filed 2026-05-06 | $20.52M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $10.04M derived: sum of 2 quarters · filed 2026-03-02 | $15.37M derived: sum of 3 quarters · filed 2026-03-02 | $19.61M 10-K · filed 2026-03-02 |
| 2024-09-30 | $4.88M 10-Q · filed 2025-11-07 | $10.21M derived: sum of 2 quarters · filed 2025-11-07 | $14.45M 10-Q · filed 2025-11-07 | $19.04M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $5.33M 10-Q · filed 2025-08-06 | $9.57M 10-Q · filed 2025-08-06 | $14.17M derived: sum of 3 quarters · filed 2026-03-02 | $19.13M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $4.24M 10-Q · filed 2025-05-07 | $8.84M derived: sum of 2 quarters · filed 2026-03-02 | $13.80M derived: sum of 3 quarters · filed 2026-03-02 | $18.54M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.56M derived: sum of 2 quarters · filed 2026-03-02 | $14.30M derived: sum of 3 quarters · filed 2026-03-02 | $18.15M 10-K · filed 2026-03-02 |
| 2023-09-30 | $4.96M 10-Q · filed 2024-11-07 | $9.70M derived: sum of 2 quarters · filed 2024-11-07 | $13.56M 10-Q · filed 2024-11-07 | $14.79M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $4.74M 10-Q · filed 2024-08-08 | $8.59M 10-Q · filed 2024-08-08 | $9.83M derived: sum of 3 quarters · filed 2025-02-27 | $10.68M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $3.85M 10-Q · filed 2024-05-02 | $5.09M derived: sum of 2 quarters · filed 2025-02-27 | $5.94M derived: sum of 3 quarters · filed 2025-02-27 | $6.27M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.09M derived: sum of 2 quarters · filed 2025-02-27 | $2.42M derived: sum of 3 quarters · filed 2025-02-27 | $2.53M 10-K · filed 2025-02-27 |
| 2022-09-30 | $852.00K 10-Q · filed 2023-11-02 | $1.18M derived: sum of 2 quarters · filed 2023-11-02 | $1.29M 10-Q · filed 2023-11-02 | $1.40M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $330.00K 10-Q · filed 2023-08-03 | $442.00K 10-Q · filed 2023-08-03 | $548.00K derived: sum of 3 quarters · filed 2024-02-28 | $660.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $112.00K 10-Q · filed 2023-05-11 | $218.00K derived: sum of 2 quarters · filed 2024-02-28 | $330.00K derived: sum of 3 quarters · filed 2024-02-28 | $466.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $218.00K derived: sum of 2 quarters · filed 2024-02-28 | $354.00K derived: sum of 3 quarters · filed 2024-02-28 | $527.00K 10-K · filed 2024-02-28 |
| 2021-09-30 | $112.00K 10-Q · filed 2022-11-07 | $248.00K derived: sum of 2 quarters · filed 2022-11-07 | $421.00K 10-Q · filed 2022-11-07 | $698.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $136.00K 10-Q · filed 2022-08-11 | $309.00K 10-Q · filed 2022-08-11 | $586.00K derived: sum of 3 quarters · filed 2023-03-16 | $908.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $173.00K 10-Q · filed 2022-05-09 | $450.00K derived: sum of 2 quarters · filed 2023-03-16 | $772.00K derived: sum of 3 quarters · filed 2023-03-16 | $1.25M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $277.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $599.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.07M derived: sum of 3 quarters · filed 2023-03-16 | $1.83M 10-K · filed 2023-03-16 |
| 2020-09-30 | $322.00K 10-Q · filed 2021-11-09 | $797.00K derived: sum of 2 quarters · filed 2021-11-09 | $1.55M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $475.00K 10-Q · filed 2021-08-16 | $1.23M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $754.00K 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $4.22M 10-K · filed 2022-03-10 | |||
| 2018-12-31 | $3.25M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |